XERIS BIOPHARMA HOLDINGS INC's ticker is and the CUSIP is 98422E103. A total of 122 filers reported holding XERIS BIOPHARMA HOLDINGS INC in Q4 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $61,000 | +45.2% | 27,347 | +47.6% | 0.00% | – |
| Q1 2024 | $42,000 | -67.9% | 18,534 | -66.5% | 0.00% | – |
| Q4 2023 | $131,000 | +204.7% | 55,304 | +142.6% | 0.00% | – |
| Q3 2023 | $43,000 | +10.3% | 22,797 | +54.2% | 0.00% | – |
| Q2 2023 | $39,000 | +129.4% | 14,782 | +41.8% | 0.00% | – |
| Q1 2023 | $17,000 | -29.2% | 10,427 | -42.9% | 0.00% | – |
| Q4 2022 | $24,000 | +166.7% | 18,257 | +250.3% | 0.00% | – |
| Q3 2022 | $9,000 | -59.1% | 5,212 | -63.7% | 0.00% | – |
| Q2 2022 | $22,000 | -80.2% | 14,345 | -67.0% | 0.00% | – |
| Q1 2022 | $111,000 | +88.1% | 43,405 | +115.9% | 0.00% | – |
| Q4 2021 | $59,000 | – | 20,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 5,113,348 | $11,505,033 | 58.31% |
| Rosalind Advisors, Inc. | 3,120,170 | $7,020,382 | 5.40% |
| MPM BioImpact LLC | 4,830,526 | $10,868,684 | 1.69% |
| Knott David M Jr | 820,000 | $1,845 | 0.74% |
| CenterBook Partners LP | 1,465,875 | $3,298,219 | 0.20% |
| Redmile Group, LLC | 1,046,587 | $2,354,821 | 0.14% |
| Alpine Global Management, LLC | 300,000 | $675,000 | 0.12% |
| GSA CAPITAL PARTNERS LLP | 605,663 | $1,363 | 0.10% |
| Invenomic Capital Management LP | 592,078 | $1,332,176 | 0.06% |
| Powell Investment Advisors, LLC | 50,000 | $112,500 | 0.06% |